Should I buy or sell bluebird bio stock right now?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for bluebird bio in the last twelve months. There are currently 1 sell rating, 7 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" BLUE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BLUE, but not buy additional shares or sell existing shares. View BLUE analyst ratings or view top-rated stocks .

What is bluebird bio's stock price target for 2024?

13 brokers have issued 1 year target prices for bluebird bio's shares. Their BLUE share price targets range from $4.21 to $13.00. On average, they predict the company's stock price to reach $7.02 in the next twelve months. This suggests a possible upside of 408.6% from the stock's current price. View analysts price targets for BLUE or view top-rated stocks among Wall Street analysts .

How have BLUE shares performed in 2023?

bluebird bio's stock was trading at $6.92 on January 1st, 2023. Since then, BLUE stock has decreased by 80.1% and is now trading at $1.38. View the best growth stocks for 2023 here .

When is bluebird bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 3rd 2024. View our BLUE earnings forecast .

How were bluebird bio's earnings last quarter?

bluebird bio, Inc. (NASDAQ:BLUE) released its earnings results on Tuesday, November, 7th. The biotechnology company reported ($0.66) earnings per share for the quarter, beating the consensus estimate of ($0.69) by $0.03. The biotechnology company had revenue of $12.40 million for the quarter, compared to analyst estimates of $13.56 million. bluebird bio had a negative net margin of 419.64% and a negative trailing twelve-month return on equity of 34.32%. The business's revenue was up 17364.8% on a year-over-year basis. During the same quarter last year, the business posted ($0.92) EPS.

What ETFs hold bluebird bio's stock?

ETFs with the largest weight of bluebird bio (NASDAQ:BLUE) stock in their portfolio include Direxion Moonshot Innovators ETF (MOON) , Virtus LifeSci Biotech Products ETF (BBP) , Global X Genomics & Biotechnology ETF (GNOM) , Horizon Kinetics Medical ETF (MEDX) ,

What is Nick Leschly's approval rating as bluebird bio's CEO?

91 employees have rated bluebird bio Chief Executive Officer Nick Leschly on Glassdoor.com . Nick Leschly has an approval rating of 74% among the company's employees.

What other stocks do shareholders of bluebird bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other bluebird bio investors own include OPKO Health (OPK) , BioMarin Pharmaceutical (BMRN) , Puma Biotechnology (PBYI) , NVIDIA (NVDA) , Gilead Sciences (GILD) , Incyte (INCY) , Micron Technology (MU) , Alibaba Group (BABA) and (MDVN) (MDVN) .

How do I buy shares of bluebird bio?

Shares of BLUE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:BLUE

bluebird bio (BLUE) Stock Price, News & Analysis

$1.38

-0.03 (-2.13%)

(As of 12/29/2023 ET)

Compare

Today's Range: $1.38
▼
$1.43
50-Day Range: $1.32
▼
$4.83
52-Week Range: $1.26
▼
$8.52

Volume: 7.59 million shs
Average Volume: 21.89 million shs
Market Capitalization: $150.89 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $7.02

bluebird bio MarketRank™ Stock Analysis

Analyst Rating: Hold
2.31 Rating Score
Upside/Downside: 408.6% Upside
$7.02 Price Target
Short Interest: Bearish
23.29% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.39
Based on 3 Articles This Week
Insider Trading: Selling Shares
$20,458 Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($1.79) to ($1.85) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.29 out of 5 stars

Medical Sector

356th out of 950 stocks

Biological Products, Except Diagnostic Industry

59th out of 158 stocks

4.2

Analyst's Opinion

Consensus Rating
bluebird bio has received a consensus rating of Hold. The company's average rating score is 2.31, and is based on 5 buy ratings, 7 hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $7.02, bluebird bio has a forecasted upside of 408.6% from its current price of $1.38.
Amount of Analyst Coverage
bluebird bio has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.0

Short Interest

Percentage of Shares Shorted
23.29% of the outstanding shares of bluebird bio have been sold short.
Short Interest Ratio / Days to Cover
bluebird bio has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in bluebird bio has recently increased by 16.57%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
bluebird bio does not currently pay a dividend.
Dividend Growth
bluebird bio does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for BLUE.

2.4

News and Social Media Coverage

News Sentiment
bluebird bio has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.84 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for bluebird bio this week, compared to 5 articles on an average week.
Search Interest
49 people have searched for BLUE on MarketBeat in the last 30 days. This is an increase of 145% compared to the previous 30 days.
MarketBeat Follows
24 people have added bluebird bio to their MarketBeat watchlist in the last 30 days. This is an increase of 700% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, bluebird bio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $20,458.00 in company stock.
Percentage Held by Insiders
Only 2.10% of the stock of bluebird bio is held by insiders.
Percentage Held by Institutions
87.43% of the stock of bluebird bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for bluebird bio are expected to decrease in the coming year, from ($1.79) to ($1.85) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of bluebird bio is -1.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of bluebird bio is -1.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
bluebird bio has a P/B Ratio of 0.58. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About bluebird bio Stock (NASDAQ:BLUE)

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.

BLUE Stock Price History

30 days | 90 days | 365 days | Advanced Chart

BLUE Stock News Headlines

December 30, 2023 | americanbankingnews.com

bluebird bio (NASDAQ:BLUE) Stock Price Passes Below 200 Day Moving Average of $3.30

December 24, 2023 | fool.com

If You Invested $10,000 in Bluebird Bio In 2021, This Is How Much You Would Have Today

December 31, 2023 | MarketBeat Internal (Ad)

MarketBeat All Access New Year's Sale - Just $1.00

Access our premier research platform that includes MarketBeat Daily Premium, portfolio monitoring tools, stock screeners, research tools, a real-time news feed, email and SMS alerts, the MarketBeat Idea Engine, proprietary brokerage rankings, extended data export tools and much more. Save 75% Your 2024 Subscription. Just $1.00 for the first 30 days.

December 23, 2023 | msn.com

1 Green Flag and 1 Red Flag for Bluebird Bio Stock

December 23, 2023 | americanbankingnews.com

bluebird bio, Inc. (NASDAQ:BLUE) Forecasted to Earn FY2023 Earnings of ($1.52) Per Share

December 22, 2023 | fool.com

3 Money-Saving Tricks for Investing in Biotech Stocks in 2024

December 22, 2023 | americanbankingnews.com

Bank of America Cuts bluebird bio (NASDAQ:BLUE) Price Target to $5.00

December 20, 2023 | finance.yahoo.com

Bluebird Bio Stock Is in Free Fall Weeks After a Landmark FDA Approval. Here’s Why.

December 31, 2023 | MarketBeat Internal (Ad)

MarketBeat All Access New Year's Sale - Just $1.00

December 20, 2023 | msn.com

bluebird bio stock slides on pricing of $125 million stock offering

December 20, 2023 | marketwatch.com

Bluebird Bio Shares Fall 45% On Stock Offering

December 20, 2023 | benzinga.com

Why Bluebird Bio Shares Are Getting Crushed Wednesday

December 19, 2023 | nasdaq.com

Bluebird Bio Prices Public Offering Of 83.33 Mln Shares At $1.50/shr; Stock Plunges

December 19, 2023 | finance.yahoo.com

bluebird bio, Inc. Announces Pricing of $125 Million Public Offering of Common Stock

December 19, 2023 | seekingalpha.com

bluebird bio's Lyfgenia: Navigating Commercialization Challenges In SCD

December 19, 2023 | bizjournals.com

Struggling bluebird aims to raise funds through stock sale, unusual financing deal

December 18, 2023 | marketwatch.com

Bluebird Bio Shares Fall 13% After Disclosing Stock Offering

December 15, 2023 | fool.com

Down 30% in a Week, What in the World Is Going On With Bluebird Bio Stock?

December 14, 2023 | news.yahoo.com

Bluebird signs pact with insurer for sickle cell gene therapy

December 14, 2023 | msn.com

bluebird bio gains on deal with commercial payer

December 13, 2023 | msn.com

InnovationRx: Tough Road Ahead For Bluebird's Gene Therapy

December 12, 2023 | msn.com

Somerville-based Bluebird Bio got its sickle cell gene therapy approved. Will it matter for the struggling biotech?

December 12, 2023 | markets.businessinsider.com

4 Analysts Have This to Say About bluebird bio

December 12, 2023 | markets.businessinsider.com

Buy Rating for Bluebird Bio: Positive Outlook Amidst Gene Therapy Launch and Competitive Market Positioning

December 11, 2023 | realmoney.thestreet.com

HSBC gets more bearish on Bluebird Bio, downgrades shares

December 11, 2023 | markets.businessinsider.com

Why bluebird bio Shares Are Trading Higher? Here Are Other Stocks Moving In Monday's Mid-Day Session

December 10, 2023 | finance.yahoo.com

Long-Term Data Presented at ASH Support beti-cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels

See More Headlines

Receive BLUE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for bluebird bio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/07/2023
Today: 12/31/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 4/03/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:BLUE
CUSIP: N/A
CIK: 1293971
Web: www.bluebirdbio.com
Phone: (339) 499-9300
Fax: N/A
Employees: 323
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $7.02
High Stock Price Target: $13.00
Low Stock Price Target: $4.21
Potential Upside/Downside: +408.6%
Consensus Rating: Hold
Rating Score (0-4): 2.31
Research Coverage: 13 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.74)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-266,580,000.00
Net Margins: -419.64%
Pretax Margin: -419.50%
Return on Equity: -34.32%
Return on Assets: -14.44%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.55
Quick Ratio: 1.42

Sales & Book Value

Annual Sales: $3.60 million
Price / Sales: 41.91
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.37 per share
Price / Book: 0.58

Miscellaneous

Outstanding Shares: 109,340,000
Free Float: 107,040,000
Market Cap: $150.89 million
Optionable: Optionable
Beta: 0.98

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

Mr. Andrew Obenshain (Age 49)
President, CEO & Director
Comp: $1.04M
Mr. Thomas J. Klima (Age 51)
Chief Commercial Officer & COO
Comp: $654.97k
Mr. Richard A. Colvin M.D. (Age 57)
Ph.D., Chief Medical Officer
Comp: $696.24k
Mr. Christopher Krawtschuk CPA (Age 49)
CFO, Principal Accounting Officer & Treasurer
Mr. Joseph D. Vittiglio Esq. (Age 51)
J.D., Chief Legal & Business Officer and Secretary
Jess Rowlands
Head of Corporate Communications
Ms. Andrea Walton
Chief People Officer
Mr. Kasra Kasraian
Senior Vice President of Technical Development & Operations
Mr. Scott Shoemaker
Senior Vice President of Quality
Ms. Sarah Alspach
Senior Vice President of External Affairs

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

BLUE Stock Analysis - Frequently Asked Questions

Should I buy or sell bluebird bio stock right now?: 13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for bluebird bio in the last twelve months. There are currently 1 sell rating, 7 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" BLUE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BLUE, but not buy additional shares or sell existing shares.
View BLUE analyst ratings or view top-rated stocks.
What is bluebird bio's stock price target for 2024?: 13 brokers have issued 1 year target prices for bluebird bio's shares. Their BLUE share price targets range from $4.21 to $13.00. On average, they predict the company's stock price to reach $7.02 in the next twelve months. This suggests a possible upside of 408.6% from the stock's current price.
View analysts price targets for BLUE or view top-rated stocks among Wall Street analysts.
How have BLUE shares performed in 2023?: bluebird bio's stock was trading at $6.92 on January 1st, 2023. Since then, BLUE stock has decreased by 80.1% and is now trading at $1.38.
View the best growth stocks for 2023 here.
When is bluebird bio's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 3rd 2024.
View our BLUE earnings forecast.
How were bluebird bio's earnings last quarter?: bluebird bio, Inc. (NASDAQ:BLUE) released its earnings results on Tuesday, November, 7th. The biotechnology company reported ($0.66) earnings per share for the quarter, beating the consensus estimate of ($0.69) by $0.03. The biotechnology company had revenue of $12.40 million for the quarter, compared to analyst estimates of $13.56 million. bluebird bio had a negative net margin of 419.64% and a negative trailing twelve-month return on equity of 34.32%. The business's revenue was up 17364.8% on a year-over-year basis. During the same quarter last year, the business posted ($0.92) EPS.

What ETFs hold bluebird bio's stock?: ETFs with the largest weight of bluebird bio (NASDAQ:BLUE) stock in their portfolio include Direxion Moonshot Innovators ETF (MOON), Virtus LifeSci Biotech Products ETF (BBP), Global X Genomics & Biotechnology ETF (GNOM), Horizon Kinetics Medical ETF (MEDX),
What is Nick Leschly's approval rating as bluebird bio's CEO?: 91 employees have rated bluebird bio Chief Executive Officer Nick Leschly on Glassdoor.com. Nick Leschly has an approval rating of 74% among the company's employees.
What other stocks do shareholders of bluebird bio own?: Based on aggregate information from My MarketBeat watchlists, some companies that other bluebird bio investors own include OPKO Health (OPK), BioMarin Pharmaceutical (BMRN), Puma Biotechnology (PBYI), NVIDIA (NVDA), Gilead Sciences (GILD), Incyte (INCY), Micron Technology (MU), Alibaba Group (BABA) and (MDVN) (MDVN).
How do I buy shares of bluebird bio?: Shares of BLUE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BLUE) was last updated on 12/31/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial